Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine, Venetoclax and Pevonedistat in Newly Diagnosed Secondary or Therapy-Related AML
NCT03862157Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2019
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of dose-limiting toxicities at 28 days, Complete response / complete response with incomplete bone marrow recovery rate at 168 days and 2 more. Started Feb 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03862157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862157.